Plain-English translation of NCT07070648 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research is testing whether two tools used together—a special blood test that detects cancer DNA and PET scans—can predict how well you'll respond to standard lymphoma chemotherapy. Newly diagnosed patients with diffuse large B-cell lymphoma will receive either R-CHOP or polatuzumab vedotin-based chemotherapy (depending on their disease severity), and researchers will collect blood samples and imaging scans at specific timepoints to see if these markers can forecast your outcome.
Current treatments work well for many lymphoma patients, but doctors don't always know early on who will respond best. By studying whether blood tests and imaging can predict treatment success after just a few cycles, this medication may help doctors make faster, smarter decisions about your care.
You likely qualify if…
You likely don't qualify if…
You will receive six cycles of intravenous chemotherapy (either R-CHOP or polatuzumab vedotin-based treatment), given over several months. During treatment, you'll have PET/CT scans at baseline, after two cycles, and at the end of treatment to measure how the cancer is responding. You'll also donate blood samples three times during the study so researchers can analyze circulating tumor DNA. The entire treatment and monitoring period takes approximately 5–6 months, with regular clinic visits for infusions and testing.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China
Sponsor
Fudan University
Enrollment target
~300 participants
Started
May 2025
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Rong Tao, M.D
Fudan University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.